Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunder Mudaliar

Showing results (21-30 of 87) with videos related to

Pageof 9
Sort By:
Advances in Therapy|November 9, 2023
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 InhibitorsSubodh Verma, Sunder Mudaliar, Peter J Greasley
Journal of Clinical Hypertension (Greenwich, Conn.)|October 2, 2010
Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertensionWilla Hsueh, Giora Davidai, Robert Henry, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 30, 2003
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implicationsSunder Mudaliar, Anna R Chang, Robert R Henry
Diabetes Care|November 26, 2015
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to BedsideSunder Mudaliar, David Polidori, Brian Zambrowicz, et al.
Schizophrenia Research|January 22, 2008
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectinHua Jin, Jonathan M Meyer, Sunder Mudaliar, et al.
Diabetes Care|January 23, 2020
A Tribute to Robert Roy Henry-The Classic "Academic Triple Threat": Accomplished Researcher, Inspiring Teacher, and Compassionate ClinicianSteven Edelman, Jerrold Olefsky, Sunder Mudaliar, et al.
The Journal of Clinical Endocrinology and Metabolism|April 28, 2012
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trialRobert R Henry, Sunder Mudaliar, Linda Kanitra, et al.
Diabetes, Obesity & Metabolism|January 19, 2017
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot studyRobert R Henry, Paresh Dandona, Jeremy Pettus, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2008
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistanceTheodore P Ciaraldi, Vanita Aroda, Sunder Mudaliar, et al.
Diabetes, Obesity & Metabolism|March 3, 2022
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practiceKamlesh Khunti, Serge Jabbour, Xavier Cos, et al.
Pageof 9

Showing results (21-30 of 87) with videos related to

Sort By:
Pageof 9
Advances in Therapy|November 9, 2023
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 InhibitorsSubodh Verma, Sunder Mudaliar, Peter J Greasley
Journal of Clinical Hypertension (Greenwich, Conn.)|October 2, 2010
Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertensionWilla Hsueh, Giora Davidai, Robert Henry, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 30, 2003
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implicationsSunder Mudaliar, Anna R Chang, Robert R Henry
Diabetes Care|November 26, 2015
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to BedsideSunder Mudaliar, David Polidori, Brian Zambrowicz, et al.
Schizophrenia Research|January 22, 2008
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectinHua Jin, Jonathan M Meyer, Sunder Mudaliar, et al.
Diabetes Care|January 23, 2020
A Tribute to Robert Roy Henry-The Classic "Academic Triple Threat": Accomplished Researcher, Inspiring Teacher, and Compassionate ClinicianSteven Edelman, Jerrold Olefsky, Sunder Mudaliar, et al.
The Journal of Clinical Endocrinology and Metabolism|April 28, 2012
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trialRobert R Henry, Sunder Mudaliar, Linda Kanitra, et al.
Diabetes, Obesity & Metabolism|January 19, 2017
Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot studyRobert R Henry, Paresh Dandona, Jeremy Pettus, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2008
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistanceTheodore P Ciaraldi, Vanita Aroda, Sunder Mudaliar, et al.
Diabetes, Obesity & Metabolism|March 3, 2022
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practiceKamlesh Khunti, Serge Jabbour, Xavier Cos, et al.
Pageof 9